|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
1981-7-23
|
|
pubmed:abstractText |
ICRF-187 (NSC-169780), the (+) enantiomer of the racemic antineoplastic agent ICRF-159 (NSc-129943), was administered intravenously for five days every three weeks to 18 patients in a phase I study. Leukopenia was the dose-limiting toxicity. Mild reversible elevations in SGOT and bilirubin were common. Other toxicities were mild and infrequent. Recommended doses of ICRF-187 for phase II studies are 800 mg/m2 for heavily pretreated patients and 1250 mg/m2 for patients with little or no prior therapy. A daily five day intravenous schedule should be used. Other potential clinical uses of ICRF-187 are discussed.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
47
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1959-62
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:6784914-Adult,
pubmed-meshheading:6784914-Dose-Response Relationship, Drug,
pubmed-meshheading:6784914-Drug Administration Schedule,
pubmed-meshheading:6784914-Drug Evaluation,
pubmed-meshheading:6784914-Granulocytes,
pubmed-meshheading:6784914-Humans,
pubmed-meshheading:6784914-Infusions, Parenteral,
pubmed-meshheading:6784914-Leukocyte Count,
pubmed-meshheading:6784914-Leukopenia,
pubmed-meshheading:6784914-Myeloproliferative Disorders,
pubmed-meshheading:6784914-Neoplasms,
pubmed-meshheading:6784914-Piperazines,
pubmed-meshheading:6784914-Platelet Count,
pubmed-meshheading:6784914-Razoxane
|
|
pubmed:year |
1981
|
|
pubmed:articleTitle |
Phase I evaluation of ICRF-187 (NSC-169780) in patients with advanced malignancy.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|
